Efficacy and safety of the first targeted biological drug dupilumab in the treatment of severe continuously relapsing atopic dermatitis
- Authors: Konnov P.E.1, Arsenieva A.A.1
-
Affiliations:
- Samara State Medical University
- Issue: Vol 99, No 1 (2023)
- Pages: 62-70
- Section: GUIDELINES FOR PRACTITIONERS
- URL: https://ogarev-online.ru/0042-4609/article/view/126202
- DOI: https://doi.org/10.25208/vdv1384
- ID: 126202
Cite item
Full Text
Abstract
In the past few decades, the prevalence of allergic dermatoses in European countries, including the Russian Federation, has increased two to three times. The skin barrier plays an essential role in preventing the penetration of allergens and microbial agents into the human body.
Atopic dermatitis is one of the most common, genetically determined skin diseases. The development of atopic dermatitis involves environmental factors that violate the skin barrier, as well as the genetic, immunological characteristics of the patient.
In modern science, the issue of pathogenetic treatment of atopic dermatitis remains not fully resolved. The problem is compounded by the fact that this disease is multifactorial, with a predominance of IgE-mediated allergic reactions, although the level of IgE does not always correlate with the severity of atopic dermatitis.
Currently, the development and implementation of genetically engineered drugs for the treatment of this pathology continues, one of these drugs is dupilumab.
The article describes the efficacy and safety of dupilumab in the treatment of severe continuously relapsing atopic dermatitis.
Full Text
##article.viewOnOriginalSite##About the authors
Pavel E. Konnov
Samara State Medical University
Author for correspondence.
Email: konnoff@yandex.ru
ORCID iD: 0000-0002-6505-7943
SPIN-code: 1698-3840
MD, Cand. Sci. (Med.), Assistant Professor
Russian Federation, SamaraAntonina A. Arsenieva
Samara State Medical University
Email: a.arsenieva2014@yandex.ru
ORCID iD: 0000-0002-7933-3515
SPIN-code: 4320-1196
MD, Cand. Sci. (Med.), Assistant Professor
Russian Federation, SamaraReferences
- Simpson EL, Irvine AD, Eichenfield LF, Friedlander SF. Update on epidemiology, diagnosis, and disease course of atopic dermatitis. Semin Cutan Med and Surg. 2016;35(5 Suppl):S84–88. doi: 10.12788/j.sder.2016.041
- Nygaard U, Vestergaard C, Deleuran M. Emerging treatment options in atopic dermatitis: systemic therapies. Dermatology. 2017;233(5):344–357. doi: 10.1159/000484406
- Rodrigues MA, Nogueira M, Torres T. Dupilumab for atopic dermatitis: evidence to date. G Ital Dermatol Venereol. 2019;154(6):696–713. doi: 10.23736/S0392-0488.19.06417-4
- Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;2(3):110–118. doi: 10.4172/2155-9899.1000110
- Круглова Л.С., Шатохина Е.А., Руднева Н.C. Эффективность и безопасность дупилумаба в комплексном лечении пациентов с тяжелым атопическим дерматитом. Медицинский алфавит. 2021;(9):39–43 [Kruglova LS, Shatokhina EA, Rudneva NS. Efficacy and safety of dupilumab in the complex treatment of patients with severe atopic dermatitis. Medicinskij alfavit. 2021;(9):39–43. (In Russ.)] doi: 10.33667/2078-5631-2021-9-39-43
- DaVeiga SP. Epidemiology of atopic dermatitis: a review. Allergy Asthma Proc. 2012;33(3):227–234. doi: 10.2500/aap.2012.33.3569
- Lund S, Walford HH, Doherty TA. Type 2 innate lymphoid cells in allergic disease. Curr Immunol Rev. 2013;9(4):214–221. doi: 10.2174/1573395510666140304235916
- Gittler JK, Krueger JG, Guttman-Yassky E. Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis. J Allergy Clin Immunol. 2013;131(2):300–313. doi: 10.1016/j.jaci.2012.06.048
- Zheng T, Oh MH, Oh SY, Schroeder JT, Glick AB, Zhu Z. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol. 2009;129(3):742–751. doi: 10.1038/jid.2008.295
- Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50. doi: 10.1038/nrd4624
- Noda S, Krueger JG, Guttman E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135(2):324–336. doi: 10.1016/j.jaci.2014.11.015
- Huang YJ, Marsland BJ, Bunyavanich S, O'Mahony L, Leung DYM, Muraro M, et al. The microbiome in allergic disease: Current understanding and future opportunities-2017 PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology. J Allergy Clin Immunol. 2017;139(4):1099–1110. doi: 10.1016/j.jaci.2017.02.007
- Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10.1056/NEJMoa1610020
- Федеральные клинические рекомендации по ведению больных атопическим дерматитом. М., 2021. 40 c. [Federal'nye klinicheskie rekomendacii po vedeniju bol'nyh atopicheskim dermatitom (Federal clinical guidelines for the management of patients with atopic dermatitis). Moscow; 2021. 40 p. (In Russ.)]
- Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol. 2015;15(5):271–282. doi: 10.1038/nri3831
- Инструкция по применению лекарственного препарата Дупиксент: регистрационное удостоверение ЛП-005440: регистрация 04.04.2019. [Instrukcija po primeneniju lekarstvennogo preparata Dupiksent: registracionnoe udostoverenie LP-005440: registracija 04.04.2019 (Instructions for the use of the drug Dupixent: registration certificate LP-005440: registration 04.04.2019). (In Russ.)] https://grls.pharm-portal.ru/grls/7e0c1e54-9770-417d-9a2c-9f371d5988e4#summary (Дата обращения: 27.12.2022).
Supplementary files
